START STRONG from the first dose and

STAY STRONG with lasting efficacy

Most of the visual gains were achieved with 1 or 2 injections1

EYLEA®-treated patients had a mean gain of +12.1 letters and 39% gained ≥3 lines at Week 24, increasing to +13.5 letters and 50% with ≥3 lines gained at Week 481

mCNV MYRROR Results: Mean change in ETDRS letters from baseline

mCNV lesion size was reduced by >50% from baseline to Week 24 in the early EYLEA treatment group1

  • Lesion size almost doubled in the delayed treatment group

mCNV leakage was resolved by Week 48 in 86% of early EYLEA-treated patients vs. 67% in the delayed treatment group.1

BCVA, best-corrected visual acuity; mCNV, myopic choroidal neovascularization; CRT, central retinal thickness; ETDRS, Early Treatment Diabetic Retinopathy Study; RCT, randomized controlled trial; VA, visual acuity.

Reference

  1. Ikuno Y, Ohno-Matsui K, Wong TY et al. Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: The MYRROR study. Ophthalmology 2015;122(6):1220–1227.